journal article·2015-11-02

Ex vivolocalization and permeation of cisplatin from novel topical formulations through excised pig, goat, and mice skin andin vitrocharacterization for effective management of skin-cited malignancies

Vandana Gupta, Piyush Trivedi

Publisher page

Abstract

CONTEXT: It would be advantageous to administer cisplatin topically for treatment of cutaneous malignancies. OBJECTIVES: Present work focuses on ex vivo and in vitro characterization of proultraflexible topical formulations. MATERIALS AND METHODS: Permeation of cisplatin through the excised pig, goat, and mice skin was quantitatively determined. RESULTS: Data indicate that protransfersome carbopol gel (pcg) formulation clearly delayed drug permeation through skin. Permeation of cisplatin from protransfersome system (ps) formulation was enhanced by approximately 1.5 fold compared with pcg for pig and goat skin. DISCUSSION: Localization of drug from pcg was higher and showed less permeation. CONCLUSION: Cisplatin-loaded pcg formulation is better to treat cutaneous malignancies.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advancements in Transdermal Drug Delivery · Skin and Cellular Biology Research · melanin and skin pigmentation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (40)

Show source-provided references
1. Alfred GG · 2001 · 1432
2. 10.1016/0731-7085(95)01544-U10.1016/0731-7085(95)01544-U ↗
3. 10.1016/0041-008X(82)90149-110.1016/0041-008X(82)90149-1 ↗
4. 10.1002/jps.260074011710.1002/jps.2600740117 ↗
5. 10.3109/0360253840903355610.3109/03602538409033556 ↗
6. 10.1191/0960327105ht537oa10.1191/0960327105ht537oa ↗
7. 10.1016/j.tiv.2006.06.00910.1016/j.tiv.2006.06.009 ↗
8. 10.1111/j.2042-7158.1992.tb05485.x10.1111/j.2042-7158.1992.tb05485.x ↗
9. 10.1016/j.tox.2006.09.01310.1016/j.tox.2006.09.013 ↗
10. 10.1016/S0378-5173(02)00221-110.1016/S0378-5173(02)00221-1 ↗
11. 10.2478/v10007-011-0004-810.2478/v10007-011-0004-8 ↗
12. 10.1007/s12272-012-0510-310.1007/s12272-012-0510-3 ↗
13. 10.1016/S1773-2247(12)50060-210.1016/S1773-2247(12)50060-2 ↗
14. 10.1016/j.ijpharm.2012.08.04010.1016/j.ijpharm.2012.08.040 ↗
15. 10.1111/j.1600-0846.2006.00179.x10.1111/j.1600-0846.2006.00179.x ↗
16. 10.1208/pt06036410.1208/pt060364 ↗
17. Jain S · Indian J Pharm Sci · 2003 · 65 · 152
18. 10.1016/0190-9622(92)70074-P10.1016/0190-9622(92)70074-P ↗
19. 10.3109/0265204980900683210.3109/02652049809006832 ↗
20. 10.1007/978-0-387-77574-6_810.1007/978-0-387-77574-6_8 ↗
21. Lin SY · Methods Find Exp Clin Pharmacol · 1992 · 14 · 645
22. 10.1016/j.vascn.2005.06.00510.1016/j.vascn.2005.06.005 ↗
23. Martindale · 2002 · 494
24. 10.1159/00040127410.1159/000401274 ↗
25. 10.1007/978-1-4615-5885-9_210.1007/978-1-4615-5885-9_2 ↗
26. Newman MD · Cutis · 2007 · 79 · 18
27. 10.1016/j.ijpharm.2006.04.00110.1016/j.ijpharm.2006.04.001 ↗
28. Panchagnula R · Exp Clin Pharmco · 1997 · 19 · 335
29. Price NM · J Drugs Dermatol · 2007 · 6 · 778
30. 10.1211/002235704444510.1211/0022357044445 ↗
31. 10.1016/j.carbpol.2012.07.06010.1016/j.carbpol.2012.07.060 ↗
32. 10.1002/jps.260080020310.1002/jps.2600800203 ↗
33. 10.1016/S0378-5173(00)00665-710.1016/S0378-5173(00)00665-7 ↗
34. 10.1081/PDT-20003143210.1081/PDT-200031432 ↗
35. 10.1016/S0923-1811(96)00508-710.1016/S0923-1811(96)00508-7 ↗
36. Torres A · J Transl Med · 2007 · 26 · 5
37. 10.1016/j.tox.2007.12.02710.1016/j.tox.2007.12.027 ↗
38. Vecchia BE · 2006 · 305
39. Walker M · Human Toxicol · 1983 · 2 · 561
40. 10.1016/S0168-3659(00)00280-710.1016/S0168-3659(00)00280-7 ↗